Representative Matters
REFERENZMANDATE
代表事项
Public Offerings
- SpringWorks Therapeutics, Inc. in its 2019 initial public offering
- Axcella Health Inc. in its 2019 initial public offering in its $60.1 million follow-on offering and subsequent $35 million “at the market” offering
- Kaleido Biosciences Inc. in its 2019 initial public offering in its $35.6 million follow-on offering
- Akero Therapeutics Inc. in its 2019 initial public offering
- Scholar Rock Holding Corporation in its 2018 initial public offering and follow-on public offering
- Neon Therapeutics, Inc. in its 2018 initial public offering
- Voyager Therapeutics, Inc. in its 2016 initial public offering
- Celyad S.A. in its 2015 U.S. initial public offering
- Blueprint Medicines Corporation in its 2015 initial public offering
- Sage Therapeutics, Inc. in its 2014initial public offering and follow-on public offerings
- Zafgen, Inc. in its 2014 initial public offering and several of its follow-on public offerings
Corporate Formations and Venture Capital Financings
- Cerevance, LLC in its $65 million Series B Preferred Unit financing
- Xilio Therapeutics, LLC in its $100 million Series B Preferred Unit financing
- Admirx Inc. in its $43 million Series A Preferred Stock financing
- SpringWorks Therapeutics, Inc. in its $125 million Series B Preferred Stock financing
- Gemini Therapeutics, Inc. in its Series B Preferred Stock financing and Series A Preferred Stock financing
- Akero Therapeutics, Inc. in its Series B Preferred Stock financing and Series A Preferred Stock financing
- Axcella Health in its Series E Preferred Stock financing
- Kaleido Biosciences Inc. in its $101 Series B Preferred Stock financing
- Cadent Therapeutics, Inc. in its $40 million Series B Preferred Stock financing
- Neon Therapeutics, Inc. in its formation, $55 million Series A Preferred Stock financing and $70 million Series B Preferred Stock financing
- Voyager Therapeutics, Inc. in its formation, $47 million Series A Preferred Stock financing and $60 million Series B Preferred Stock financing
- Mevion Medical Systems, Inc. in connection with its up to $200 million Series F Preferred Stock financing
- SetPoint Medical Corporation in connection with its $15 million Series C-1 Preferred Stock financing,$27 million Series C Preferred Stock financing and $35 million Series C-2 Preferred Stock financing
- Scholar Rock Holding Corporation in its Series C Preferred Stock financing, Series B Preferred Unit financing and its Series A Preferred Unit financing
- RaNA Therapeutics, LLC in its Series B Preferred Unit financing
- iWalk, Inc. in its Series E Preferred Stock financing
- NinePoint Medical, Inc. in its $34 million Series B Preferred Stock financing and Series C Preferred Stock financing
- Cerevance, LLC in its Series A Preferred Unit financing
- Accelerator IV-New York Corporation and Accelerator IV-Seattle Corporation in their formation and funding
- AgTech Accelerator Corporation in its formation and initial funding
Mergers and Acquisitions and Strategic Collaborations
- Flexion Therapeutics in its licensing agreement with HK Tainuo for the development and commercialization of Flexion’s product ZILRETTA® in Greater China
- Mevion Medical Systems, Inc. in connection with its merger transaction
- Acetylon Pharmaceuticals, Inc. in its up to $1.7 billion collaboration and buyout option transaction with Celgene Corporation, and subsequent Share Purchase Transaction with Celgene Corporation
- Abide Therapeutics, Inc. in its collaboration and buyout option transaction with Celgene Corporation
- ZOLL Medical Corporation in its acquisition of Advanced Circulatory Systems, Inc.
- ZOLL Medical Corporation in its acquisition of the assets of Impact Instrumentation, Inc.
- Nimbus Therapeutics, Inc. in connection with its innovative collaborations with Monsanto and Shire Plc
- BionX Medical Technologies, Inc. in connection with its merger with Ottobock
Professional Experience
Ms. Burlingame is a member of Women Entrepreneurs in Science and Technology (WEST) and through the firm is a member of the Massachusetts Biotechnology Council (MBC) and MassMEDIC. She is also a member of the American and Boston Bar Associations.
Ms. Burlingame is a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. Ms. Burlingame has served as a workshop speaker and advisor to the Boston Pipeline Angels for the past several years and has provided advice to start-up companies and entrepreneurs through participation in events and office hours held by Harvard University and M.I.T.
Ms. Burlingame is a member of the Board of Directors of Sitters Without Borders, a member of the Board of Directors of Tailored for Success and a member of the Board of Directors of Mass AWIS.
